About Grail
GRAIL is a healthcare company focused on alleviating the global burden of cancer through early detection. Founded in 2016 as a spinout from Illumina, GRAIL pioneered the multi-cancer early detection (MCED) category after discovering that cell-free DNA from cancer could be detected in blood samples. The company's flagship product, the Galleri test, is a first-of-its-kind blood test capable of screening for signals from more than 50 types of cancer before symptoms appear, including many cancers that lack recommended screening tests today. GRAIL combines the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to revolutionize cancer screening. The company operates CAP-accredited, CLIA-certified laboratory facilities exceeding 170,000 square feet with capacity to support multiple years of growth. GRAIL serves healthcare systems, providers, payers, and individual patients primarily in the United States and United Kingdom. The company has enrolled over 380,000 participants across its unprecedented clinical program, generating more than 300 scientific publications and presentations. GRAIL's mission is to detect cancer early when it can be cured, fundamentally changing the cancer continuum from late-stage diagnosis to early intervention.
Mission & Story
Mission
Detect cancer early, when it can be cured.
Founding Story
GRAIL was founded in 2016 after an unexpected discovery in 2015 when Illumina's non-invasive prenatal test (NIPT) detected genomic abnormalities in pregnant mothers unrelated to their children's health—the test had detected cell-free DNA from cancer present in the mother's blood. Illumina spun out GRAIL as a separate entity to focus on researching this breakthrough, naming it GRAIL because co-founders believed a simple blood test could be the 'holy GRAIL' of cancer detection.
Clinical Focus
Medical conditions and clinical areas addressed by Grail.
Who It Serves
Milestones & Awards
Recent Milestones
FDA Premarket Approval Application submitted January 2026; ASCO 2026 presentations of NHS-Galleri and PATHFINDER 2 results (May-June 2026); Epic EHR integration announced April 2026; $110M equity financing with Samsung entities June 2026; Q1 2026 financial results reported May 2026
Awards & Recognition
2025 Best Place to Work (Built In & BioSpace), 2023 Change the World List (Fortune), 2022 World Changing Ideas Awards (Fast Company), Breakthroughs of the Year 2022 (The Atlantic), Intelligent Diagnostics Silver Winner 2023 (Edison Awards), Best Inventions of 2022 (Time Magazine)
Key Partnerships
Social & Media
Latest Updates
Not All MCED Tests are Created Equal: The Realities of MCED Test Development and Validation
Why Finding Cancers Before It’s Too Late Matters More Than Ever
GRAIL Update on the Accelerated Implementation of Multi-Cancer Early Detection Technology by NHS England
Making Sense of the Numbers: Interpreting Multi-Cancer Early Detection Test Performance
The NHS-Galleri trial: What to expect in 2026 from the world’s first randomized controlled trial of a Multi-Cancer Early Detection test, Galleri®
Company Details
- Founded
- 2016
- Headquarters
- Menlo Park, CA, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.